Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 2/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647357 | 0.90 | DPP4 (0.47) | DPP4CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL3907836 | 0.90 | DPP4 (0.61) | DPP4CYP3A4CYP2D6CYP1A2KCNH2 | |
| SCHEMBL3906776 | 0.90 | DPP4 (0.61) | DPP4CYP3A4CYP2D6CYP1A2KCNH2 | |
| SCHEMBL13647466 | 0.89 | DPP4 (0.49) | DPP4CYP3A4CYP2D6CYP1A2FAP | |
| SCHEMBL921182 | 0.85 | DPP4 (0.47) | DPP4CYP3A4CYP2D6CYP1A2FAP | |
| SCHEMBL13647479 | 0.84 | DPP4 (0.58) | DPP4CYP3A4CYP2D6FAPKDM4D | |
| SCHEMBL14648441 | 0.82 | DPP4 (0.68) | DPP4CYP3A4CYP2D6CYP1A2KCNH2 | |
| SCHEMBL171020 | 0.81 | DPP4 (0.77) | DPP4CYP3A4CYP2D6CYP1A2KCNH2 | |
| SCHEMBL30065223 | 0.81 | DPP4 (0.77) | DPP4CYP3A4CYP2D6CYP1A2KCNH2 | |
| Water SCHEMBL4313660 | 0.81 | DPP4 (0.79) | DPP4CYP3A4CYP2D6CYP1A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 6/4885CYP2D6 13/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 6/4885CYP2D6 15/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | DPP4 1/4885CYP3A4 6/4885CYP2D6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.